New York recalls
4,189 federal recalls affecting New York in the last 12 months - 434 New York-specific plus 3,755 nationwide. Sourced from CPSC, FDA, USDA, and NHTSA.
- 2026-04-15FDA-FoodAyco FarmsClass IDon't eat Ayco fresh cantaloupe
Ayco Farms cantaloupe may be contaminated with Salmonella, a bacteria that can cause serious foodborne illness. The affected melons were distributed to Pennsylvania, Florida, California, and New York. No illnesses have been reported so far.
- 2026-04-15FDA-FoodRiverence ProvisionsClass IIStop using Riverence Smoked Trout Dip
Riverence Provisions LLC is recalling Smoked Trout Dip because the label does not declare milk, even though the product contains cream cheese and sour cream. People with milk allergies could have a serious reaction if they eat this product. The recall affects specific lot numbers distributed across several states.
- 2026-04-15FDA-FoodMei Yu Cheng DaClass IIIDo not eat Mei Yu Cheng Da Trading olive skewers
Mei Yu Cheng Da Trading olive skewers contain cyclamates, a sweetener banned for use in food in the United States. The product was distributed in New York, Pennsylvania, and Florida. No injuries have been reported so far.
- 2026-04-15FDA-FoodMei Yu Cheng DaClass IIIDo not eat Dadi Nongfu chili vegetables
Dadi Nongfu brand dried salt chili vegetables contain cyclamates, a sweetener banned for food use in the United States. The product was distributed in New York, Pennsylvania, and Florida. No injuries have been reported.
- 2026-04-15FDA-FoodConnecticut CrabClass IIStop using Connecticut Crab Company crab cakes
Connecticut Crab Company LLC is recalling crab cakes produced on March 9, 11, 13, 16, and 18, 2026, that may have been stored at unsafe temperatures. This could allow dangerous bacteria called Clostridium botulinum to grow. The affected crab cakes were sold to food service businesses in New York and New Jersey.
- 2026-04-15FDA-DrugTevaClass IINationwideStop using recalled Teva Clonidine patches
Teva Pharmaceuticals is recalling specific batches of Clonidine Transdermal System patches (0.3 mg/day) because they were manufactured using an unapproved raw material that does not meet quality standards. The affected patches were distributed in the U.S. No injuries have been reported.
- 2026-04-15FDA-DrugTevaClass IINationwideCheck your Clonidine patch lot numbers
Teva Pharmaceuticals is recalling specific lots of Clonidine Transdermal System (0.2 mg/day) patches because they were made with an unapproved raw material that does not meet manufacturing standards. Two lots are affected: 100060002 (expires 07/2026) and 100066802 (expires 05/2027). No injuries have been reported.
- 2026-04-15FDA-DrugTevaClass IINationwideStop using recalled Teva Clonidine patches
Teva Pharmaceuticals is recalling certain Clonidine Transdermal System patches (0.1 mg/day) because they were manufactured using an unapproved raw material that does not meet FDA standards. The affected patches were distributed in the U.S. The company and FDA are working to ensure the product is removed from use.
- 2026-04-15FDA-DrugGE HealthcareClass IINationwideCheck Omnipaque injection lot numbers immediately
GE Healthcare discovered particles in certain vials of Omnipaque (iohexol), a contrast dye used during medical imaging procedures. The contamination affects 11 specific lot numbers distributed nationwide. No injuries have been reported so far.
- 2026-04-15FDA-DrugGE HealthcareClass IINationwideCheck GE Healthcare Omnipaque injection lot numbers
GE Healthcare has recalled specific lots of Omnipaque (iohexol) injection, a contrast dye used in medical imaging, because some vials may contain visible particles. This could affect the safety of the procedure if the contaminated solution is used.
- 2026-04-15FDA-DrugViatris, Inc.Class IINationwideCheck your Xanax XR 3 mg prescription bottle
Viatris is recalling one lot of Xanax XR (alprazolam) 3 mg extended-release tablets because they failed to meet dissolution specifications—meaning the tablets may not break down and release the medication properly in your body. This affects only lot #8177156 with an expiration date of 02/28/2027, distributed nationwide. No injuries have been reported.
- 2026-04-15FDA-DrugPreferred Pharmaceuticals, Inc.Class IINationwideStop using Preferred Pharmaceuticals Artificial Tears
Preferred Pharmaceuticals' Artificial Tears Lubricant Eye Drops in 0.5 oz bottles may not be sterile due to a manufacturing issue. The FDA is recalling specific lots because sterility cannot be assured. No injuries have been reported.
- 2026-04-15FDA-DrugFagron Compounding ServicesClass IINationwideStop using Fagron Vancomycin HCL IV bags
Fagron Compounding Services is recalling specific lots of Vancomycin HCL injections due to two safety concerns: the bags may not be sterile, and a blue plastic part on the administration port could detach during use. The recall affects over 11,600 bags distributed nationwide.
- 2026-04-15FDA-DrugFagron Compounding ServicesClass IINationwideVancomycin HCI, 1.5 grams added to 250 mL, 0.9% Sodium Chloride Injection USP, Fagron Sterile Services, 8710 34th St. N. Wichita, KS 67226, NDC 71266-5085-01
Lack of Assurance of Sterility; blue Break-Off-Part could detach from the administration port
- 2026-04-15FDA-DrugFagronClass IINationwideVancomycin HCI, 1.25 grams added to 250 mL, 0.9% Sodium Chloride Injection USP, Fagron Sterile Services, 8710 34th St. N. Wichita, KS 67226, NDC 71266-5083-01
Lack of Assurance of Sterility; blue Break-Off-Part could detach from the administration port
- 2026-04-15FDA-DrugFagron Compounding ServicesClass IINationwideStop using Fagron norepinephrine injection
Fagron Compounding Services is recalling norepinephrine bitartrate injection due to two issues: the sterility of the product cannot be assured, and a blue plastic part on the administration port may detach during use. This medication is used in hospitals and medical facilities to treat critical conditions. Six specific lots distributed nationwide are affected.
- 2026-04-15FDA-DrugFagron Compounding ServicesClass IINationwideDo not use Fagron norepinephrine injection
Fagron Compounding Services is recalling specific lots of norepinephrine bitartrate injection due to two concerns: the product may not be sterile, and a blue plastic piece on the administration port could detach during use. This medication is used in hospitals and clinical settings to support blood pressure in critically ill patients.
- 2026-04-15FDA-DrugFresenius KabiClass IINationwideStop using Fresenius Kabi dextrose injection
Fresenius Kabi USA is recalling a specific batch of 5% Dextrose Injection due to concerns that the product may not meet sterility standards. This injectable solution is used in medical settings to deliver fluids and glucose to patients. The affected batch (6402165, expiring 05/30/2028) was distributed nationwide.
- 2026-04-15FDA-DrugFresenius KabiClass IINationwideDo not use Fresenius Kabi dextrose injection
Fresenius Kabi is recalling specific batches of 5% Dextrose Injection because the company cannot guarantee the product is sterile. This intravenous solution is used in hospitals and medical settings. The affected batches have expiration dates of February 28, 2027.
- 2026-04-15FDA-DrugFresenius KabiClass IINationwideStop using Fresenius Kabi dextrose injection
Fresenius Kabi is recalling a specific batch of 5% Dextrose Injection due to lack of assurance of sterility. The affected product is in 50 mL freeflex bags. This intravenous medication was distributed nationwide, including Alaska and Puerto Rico.
- 2026-04-15FDA-DrugFresenius KabiClass IINationwideStop using Fresenius Kabi sodium chloride injection
Fresenius Kabi USA is recalling a specific batch of 0.9% Sodium Chloride Injection (a sterile saline solution used in medical settings) because the manufacturer cannot guarantee it remained sterile during production. The affected batch (24EU10010) was distributed nationwide, including Alaska and Puerto Rico.
- 2026-04-15FDA-DrugFresenius KabiClass IINationwideStop using Fresenius Kabi saline injection
Fresenius Kabi is recalling specific batches of 0.9% sodium chloride injection (saline) in 1,000 mL freeflex bags due to lack of assurance of sterility. The affected batches were distributed nationwide, including Alaska and Puerto Rico. No injuries have been reported.
- 2026-04-15FDA-DrugFresenius KabiClass IINationwideStop using Fresenius Kabi saline injection
Fresenius Kabi is recalling specific batches of 0.9% Sodium Chloride Injection (saline solution) used in medical settings because the manufacturer cannot guarantee the product is sterile. The affected batches were distributed nationwide. No injuries have been reported so far.
- 2026-04-15FDA-DrugFresenius KabiClass IINationwide0.9% Sodium Chloride Injection, USP, 900 mg per 100 mL (9 mg per mL) 250 mL in a Single Dose freeflex bag, Rx only, BD Becton, Dickson and Company, 1 Beckton Drive, Franklin Lakes, NJ 07417, Distributed by BD, Manufactured by: Fresenius Kabi USA, LLC ("Fresenius Kabi"), Unit of Sale NDC Number: 17271-701-05.
Lack of Assurance of Sterility
- 2026-04-15FDA-DrugFresenius KabiClass IINationwideDo not use Fresenius Kabi saline injection
Fresenius Kabi USA is recalling specific batches of 0.9% Sodium Chloride Injection (a sterile saline solution) because the manufacturer cannot guarantee the product is free from contamination. The affected batches were distributed nationwide, including Alaska and Puerto Rico, between now and June 2027.
- 2026-04-15FDA-DrugFresenius KabiClass IINationwideStop using Fresenius Kabi saline injection
Fresenius Kabi USA is recalling specific batches of 0.9% Sodium Chloride Injection (saline) because the manufacturer cannot confirm the product is sterile. Sterility is critical for injectable medications. The affected batches have expiration dates of October 31, 2026, or November 30, 2026.
- 2026-04-15FDA-DrugFresenius KabiClass IINationwideStop using Fresenius Kabi sodium chloride injection
Fresenius Kabi is recalling specific batches of 0.9% Sodium Chloride Injection due to a lack of assurance that the product is sterile. This injectable solution is used in medical settings and could pose a risk if contaminated. No injuries have been reported to date.
- 2026-04-15FDA-DrugFresenius KabiClass IINationwideStop using Fresenius Kabi saline injection
Fresenius Kabi USA is recalling multiple batches of 0.9% Sodium Chloride Injection (saline solution) used for medical purposes because the manufacturer cannot guarantee the product is sterile. The affected batches were distributed nationwide, Alaska, and Puerto Rico. No injuries have been reported.
- 2026-04-15FDA-DrugFresenius KabiClass IINationwideStop using Fresenius Kabi saline injection
Fresenius Kabi is recalling specific batches of 0.9% Sodium Chloride Injection (saline) in 100 mL bags due to lack of assurance of sterility. The affected batches were distributed nationwide, including Alaska and Puerto Rico. No injuries have been reported.
- 2026-04-15FDA-DrugFresenius KabiClass IINationwideStop using Fresenius Kabi saline injection
Fresenius Kabi is recalling specific batches of 0.9% Sodium Chloride Injection because the manufacturer cannot guarantee these vials are sterile. This injectable medication is used in hospitals and clinical settings. No injuries have been reported.
Get notified about new New York recalls
Free weekly digest. Add New York to your profile to filter alerts to your state.